DB:8BT

Stock Analysis Report

Executive Summary

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has BriaCell Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8BT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

8BT

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

28938.5%

8BT

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 8BT exceeded the German Biotechs industry which returned 10% over the past year.

Return vs Market: 8BT exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

8BTIndustryMarket
7 Day-8.5%0.4%-0.9%
30 Day39.3%-3.2%-0.4%
90 Day59115.7%4.6%2.3%
1 Year28938.5%28938.5%10.3%10.0%16.3%12.8%
3 Year12077.4%12077.4%49.4%47.8%15.8%5.7%
5 Yearn/a13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is BriaCell Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BriaCell Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether BriaCell Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BriaCell Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 8BT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BriaCell Therapeutics regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is BriaCell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BriaCell Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BriaCell Therapeutics performed over the past 5 years?

-26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8BT is currently unprofitable.

Growing Profit Margin: 8BT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8BT is unprofitable, and losses have increased over the past 5 years at a rate of -26.1% per year.

Accelerating Growth: Unable to compare 8BT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8BT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 8BT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BriaCell Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 8BT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 8BT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 8BT is debt free.

Reducing Debt: 8BT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 8BT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 8BT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8BT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 8BT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -37.6% each year


Next Steps

Dividend

What is BriaCell Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 8BT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8BT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8BT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8BT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8BT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Bill Williams 0

3.3yrs

Tenure

CA$227,755

Compensation

Dr. William V. Williams, M.D. also known as Bill, has been the Chief Executive Officer, President and Director of BriaCell Therapeutics Corp. since November 11, 2016. Dr. Williams is a seasoned biopharmace ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD413.13K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director3.3yrsCA$227.76k9.26% CA$1.1m
Charles Wiseman
Founder & Director5.3yrsCA$83.56k6.18% CA$714.7k
Gadi Levin
CFO & Corporate Secretary4yrsCA$56.07k0.11% CA$13.0k
Farrah Dean
Manager of Corporate Development0yrsno datano data

4.0yrs

Average Tenure

Experienced Management: 8BT's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director3.3yrsCA$227.76k9.26% CA$1.1m
Charles Wiseman
Founder & Director5.3yrsCA$83.56k6.18% CA$714.7k
Robert Williams
Member of Scientific Advisory Board2.8yrsno datano data
Brian Metcalf
Member of Scientific Advisory Board2.8yrsno datano data
Rebecca Taub
Independent Director1.9yrsno datano data
Vaughn Embro-Pantalony
Independent Director1.9yrsno data1.32% CA$152.6k
Douglas Faller
Member of Scientific Advisory Board2.8yrsno datano data
Thomas Kieber-Emmons
Member of Scientific Advisory Board2.8yrsno datano data
Maria Trojanowska
Member of Scientific Advisory Board2.8yrsno datano data
Jamieson Bondarenko
Chairman of the Board0.9yrsCA$3.00k16.6% CA$1.9m

2.8yrs

Average Tenure

67yo

Average Age

Experienced Board: 8BT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.5%.


Top Shareholders

Company Information

BriaCell Therapeutics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BriaCell Therapeutics Corp.
  • Ticker: 8BT
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$16.605m
  • Listing Market Cap: CA$11.569m
  • Shares outstanding: 721.96k
  • Website: https://www.briacell.com

Number of Employees


Location

  • BriaCell Therapeutics Corp.
  • Bellevue Centre
  • Suite 300
  • West Vancouver
  • British Columbia
  • V7T 2X1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCTTSXV (TSX Venture Exchange)YesCommon SharesCACADNov 2014
BCTX.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2014
8BTDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2014

Biography

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer. The company, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. It also develops Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. The company was incorporated in 2006 and is headquartered in West Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 23:37
End of Day Share Price2020/02/21 00:00
Earnings2019/10/31
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.